Table 1.

Baseline Characteristics of the 50 Study Patients.^*

Characteristic	Value
Age — yr
Median	67.5
Range	40.8–79.3
Time since initial diagnosis of prostate     adenocarcinoma — yr
Median	5.0
Interquartile range	3.4–7.9
Metastatic disease at initial diagnosis — no. (%)	23 (46)
Time since confirmation of CRPC — yr
Median	2.2
Interquartile range	1.7–3.9
PSA — ng/ml
Median	349.5
Interquartile range	153–806
CTC count — no. of cells/7.5 ml of blood
Median	37
Interquartile range	14–110
ECOG performance-status score — no. (%)†
0	9 (18)
1	35 (70)
2	6 (12)
Received prior regimens for CRPC — no. (%)
2	3 (6)
3	7 (14)
≥4	40 (80)
Received prior treatments — no. (%)
Radical prostatectomy or radiotherapy	25 (50)
Castration (chemical or surgical)	50 (100)
Abiraterone acetate	48 (96)
Enzalutamide	14 (28)
Docetaxel	50 (100)
Cabazitaxel	29 (58)
Radium-223	1 (2)

^*CRPC denotes castration-resistant prostate cancer, CTC circulating tumor-cell, and PSA prostate-specific antigen.

^†The Eastern Cooperative Oncology Group (ECOG) performance-status score ranges from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.